Short Interest in Tempest Therapeutics, Inc. (NASDAQ:TPST) Declines By 38.3%

Tempest Therapeutics, Inc. (NASDAQ:TPST) was the target of a large drop in short interest in April. As of April 30th, there was short interest totaling 395,021 shares, a drop of 38.3% from the April 15th total of 640,470 shares. Approximately 2.9% of the company’s stock are short sold. Based on an average daily volume of 241,206 shares, the short-interest ratio is currently 1.6 days.

Tempest Therapeutics Trading Down 12.4%

NASDAQ TPST traded down $0.26 during trading hours on Friday, reaching $1.83. 270,577 shares of the company traded hands, compared to its average volume of 173,402. Tempest Therapeutics has a 12 month low of $1.50 and a 12 month high of $12.23. The stock has a market capitalization of $26.25 million, a PE ratio of -0.30 and a beta of -1.75. The company has a 50 day moving average of $1.94 and a two-hundred day moving average of $3.35.

Tempest Therapeutics (NASDAQ:TPST) last posted its quarterly earnings data on Friday, May 15th. The company reported ($2.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($2.25). On average, equities research analysts anticipate that Tempest Therapeutics will post -1.34 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms recently weighed in on TPST. Zacks Research lowered shares of Tempest Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday. Wall Street Zen downgraded shares of Tempest Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Reduce”.

Insiders Place Their Bets

In other news, CEO Matthew Angel purchased 231,482 shares of the stock in a transaction that occurred on Tuesday, March 24th. The stock was acquired at an average cost of $2.16 per share, with a total value of $500,001.12. Following the acquisition, the chief executive officer owned 231,482 shares in the company, valued at approximately $500,001.12. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 6.28% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in TPST. Vanguard Group Inc. lifted its position in shares of Tempest Therapeutics by 20.8% in the 3rd quarter. Vanguard Group Inc. now owns 162,560 shares of the company’s stock worth $1,671,000 after buying an additional 27,952 shares during the last quarter. Dimensional Fund Advisors LP bought a new position in shares of Tempest Therapeutics in the 4th quarter worth about $33,000. Finally, Sabby Management LLC bought a new position in shares of Tempest Therapeutics in the 4th quarter worth about $513,000. 22.52% of the stock is currently owned by institutional investors.

Tempest Therapeutics Company Profile

Tempest Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.